PhaseBio Pharmaceuticals ROE

ROE of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2020 was -566.86% (a 700.88% increase from previous year)
  • Annual ROE for 2019 was -70.78% (a -168.99% decrease from previous year)
  • Annual ROE for 2018 was 102.59% (a 824.23% increase from previous year)
  • Twelve month ROE ending September 29, 2021 was 514.76% (a -116.65% decrease compared to previous quarter)
  • Twelve month trailing ROE decreased by -190.81% year-over-year
Trailing ROE for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
514.76% -3091.02% -358.72% -566.86%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of PhaseBio Pharmaceuticals

Most recent ROEof PHAS including historical data for past 10 years.

Interactive Chart of ROE of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -566.86%
2019 -70.78%
2018 102.59%
2017 11.1%
2016 0.0%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.